Meningitis Vaccine Project

Toward the end of epidemics

We’re working to stop meningitis in Africa

In response to the largest meningitis epidemic in African history, PATH began working in partnership with the World Health Organization on the Meningitis Vaccine Project (MVP) to eliminate meningitis as a public health problem in sub-Saharan Africa through the development, testing, introduction, and widespread use of conjugate meningococcal vaccines.

Our progress so far

Working with the Serum Institute of India Private Ltd. and partners across the world, MVP developed an effective, affordable vaccine that targets the pathogen that causes most epidemics in sub-Saharan Africa: group A Neisseria meningitidis. The vaccine, called MenAfriVac®, was developed in less than ten years and at one-tenth the cost of a typical vaccine.

Introduction of MenAfriVac® through immunization campaigns began in December 2010. Since then, mass immunization campaigns in 15 countries have reached more than 217 million people since the vaccine was launched in 2010, with 63 million vaccinated in 2014 alone. With this highly effective vaccine, the recurring epidemics–affecting thousands of infants, children, and young people–have been eliminated.

While the MVP project has met its objectives and wrapped up, the work goes on. PATH is working with in-country and global partners to ensure the use of MenAfriVac® is implemented into standard childhood immunization programs and to ensure that the long-term control of Meningitis A epidemics in the meningitis belt is sustained.

MVP Access Program open to researchers

The clinical trials of MenAfriVac® conducted in India and in Africa included an overall total of approximately 11,100 volunteers and generated a significant collection of medical and laboratory data in the MVP Database. In addition, the MVP Sera Bank includes approximately 81,000 remaining vials of sera from the MVP clinical studies conducted in Africa.

Researchers conducting studies related to meningococcal disease and generally on vaccine preventable diseases can submit research proposals to access the data and/or sera, provided that:

  • The proposed research is in the public health interest, and does not include genetic research.
  • Researchers agree to comply with the laws, regulations, research standards, and ethical standards governing the MVP Clinical Study protocols and informed consents.

To find out more about the available data and sera, and how to submit a proposal, please email meningitisresearch@path.org.

MenAfriVac is a registered trademark of Serum Institute of India Private Ltd.

Banner photo: PATH.

Comments are closed.